GAIA is well-established, with more than 20 years of experience, and has been operating cash-flow positive since its inception. From the beginning, GAIA’s focus has been on being an innovative R&D company.
The company has over 25 digital therapeutics (DTx) products. These products have been examined in more than 20 randomized clinical trials, involving over 7,000 patients, and have appeared in leading medical journals such as The Lancet Digital Health.
GAIA’s digital therapeutics offer the same effect sizes and safety profiles as modern medications. They treat patients suffering from serious diseases such as depression, anxiety, multiple sclerosis, psoriasis, and long-COVID. Additionally, GAIA has developed therapies to support comorbidities for those suffering from cancer, epilepsy, and hypertension.
These products are developed as therapeutic solutions for physicians, psychotherapists, and payers who require reliable effect sizes and cost savings.
One of GAIA’s most-researched products is deprexis, an online program for the treatment of depression. It has been shown to effectively reduce symptoms of depression in 15 randomized controlled trials as well as in real-life clinical settings, with effect sizes similar to those of antidepressants.
GAIA’s platform, ‘broca,’ is an artificial intelligence engine using both machine learning and, most recently, probability models. The original platform was developed in collaboration with the aerospace corporation Airbus over a decade ago.
The company employs around 250 multidisciplinary experts from various fields, including physicians, psychotherapists, software engineers, legal and regulatory staff, and market access specialists.
GAIA has partnerships with teams from leading universities and corporations around the world. Currently, these partnerships span multiple geographies, including Europe, Asia, South America, and North America.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze